Search results: (10000)
News Assessment of the Effectiveness of Superabsorbent Dressings from the Perspective of Doctors and Patients
The Journal of Wound Care published the results of an observational study on the benefits of Resposorb Super superabsorbent dressings in the treatment of acute and chronic wounds with higher levels of exudate.
News Options for Tapering TPO-RA in ITP Patients: Practical Experience and Expert Consensus
A recently published British study aims to provide recommendations on tapering TPO-RA in patients with immune thrombocytopenia (ITP) based on existing evidence, survey results of clinical practice among hematologists, and expert consensus.
News Effect of Romiplostim in Refractory ITP with Possibility of Maintaining Response Without Treatment – Case Report
This case report from the United States features an ideal therapeutic response to romiplostim in a patient with refractory immune thrombocytopenia (ITP). After several years of successful therapy, the medication could even be gradually discontinued while maintaining the therapeutic response.
News Newer Beta Blockers Offered for Use in Atherosclerosis Prevention
An article highlighting recent scientific findings on the beneficial effects of beta-blockers (BB) directly on the arterial wall and the potential benefit for the prevention of atherosclerotic cardiovascular disease (ASCVD) by adding BB to already established strategies for treating dyslipidemia and diabetes was published this year in the journal Current Atherosclerosis Reports.
News Will up-titration or combination with bisoprolol help to better control hypertension in amlodipine users?
Will patients with hypertension who do not achieve control of this condition with amlodipine at a dose of 5 mg benefit more from up-titration or combining it with bisoprolol? The answer to this question was sought in a study published this year by German authors.
News EMPATHY Questionnaire as a Tool for Better Personalization of Levothyroxine Doses in Patients with Primary Hypothyroidism?
The therapy for hypothyroidism consists of substitution with levothyroxine (L-T4). Failure to achieve the target thyrotropin hormone (TSH) level can be due to non-compliance (in 60% of cases) or malabsorption of the drug (in 40%). The aim of the presented Italian study was the validation of the EMPATHY questionnaire for better personalization of therapy.
News Can Thyroid Hormone Supplementation Reduce the Risk of Cognitive Disorders?
The recent systematic literature review presented below, published by authors from the California Institute of Behavioral Neurosciences and Psychology (CIBNP), focused, among other things, on potential associations between hypothyroidism and dementia and the impact of related therapeutic interventions in terms of improving cognitive functions.
News Administration of RAAS Inhibitors in Czech Patients with Heart Failure in Real Practice
A partial analysis of data from the national register of reimbursed health care focused on the epidemiology of heart failure in the Czech Republic showed how inhibitors of the renin-angiotensin-aldosterone system (RAAS), i.e., angiotensin-converting enzyme inhibitors (ACEi), AT1 receptor blockers for angiotensin II (ARBs, sartans), and angiotensin receptor and neprilysin inhibitors (ARNI), were used in real practice in the years 2012–2018 in patients with this disease.
News Transition from Risperidone to Lurasidone and Adjustment of Metabolic Profile in Patients with Stable Schizophrenia
Patients with schizophrenia have a higher risk of cardiometabolic diseases compared to the general population, which is further increased by certain antipsychotics. A recently published post hoc analysis assessed, among other things, the metabolic parameters of patients who switched from risperidone therapy to lurasidone.
News Brigatinib in Patients with ALK+ NSCLC – Final Results of the J-ALTA Clinical Study
At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early June 2022, the final results of the J-ALTA clinical study were presented. So how did brigatinib perform in the treatment of patients with ALK-positive NSCLC who were refractory to alectinib?
News Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib
Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect in patients who have developed resistance during treatment with other ALK inhibitors. It has demonstrated efficacy in patients with ALK+ non-small cell lung cancer (NSCLC) who are refractory to crizotinib as well as in ALK+ NSCLC not previously treated with an ALK inhibitor. Post hoc analysis of the ALTA-1L trial, presented as a poster at this year's American Society of Clinical Oncology (ASCO) annual meeting, addresses whether the maximum reduction in target lesions of ALK+ NSCLC treated with brigatinib or crizotinib correlates with overall survival (OS) and progression-free survival (PFS).
News Association of Low TSH Levels in Hypothyroidism Therapy with Mortality Risk
Community surveys indicate that up to 53% of patients treated for hypothyroidism have serum thyroid-stimulating hormone (TSH) levels outside the normal range at some point. The negative effect of TSH levels above the upper reference limit is well documented, but according to two recently published population studies, mortality in patients treated with levothyroxine is also increased when TSH levels are below the lower reference limit.
News ID 360 – Immunodeficiency in Interdisciplinary Collaboration 2022
For the second time, a two-day meeting titled "ID 360 – Immunodeficiency in Interdisciplinary Collaboration" took place, this time on March 25–26, 2022, in Prague. Several current topics were discussed during this professional event, which brings together experts who care for patients with primary or secondary immunodeficiencies. The meeting was professionally guaranteed by Prof. MUDr. Anna Šedivá, DSc., from the Institute of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital Motol in Prague.
News Current and Future Possibilities for Influencing Immune Thrombocytopenia
The possibilities for treating immune thrombocytopenia (ITP) are quite broad today, with a major advancement for many patients being the advent of thrombopoietin receptor agonists. However, for some patients, optimal treatment is still not available, and their hope lies in further research.
News Romiplostim in a Pregnant Woman − Case Report
The following clinical case demonstrates good control of resistant immune thrombocytopenia in a pregnant woman during the administration of romiplostim.